Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents

被引:3
|
作者
Yin, Jiasheng [1 ]
Shen, Li [1 ,2 ]
Ji, Meng [1 ]
Wu, Yizhe [1 ,2 ]
Cai, Sishi [1 ]
Chen, Jiahui [1 ,2 ]
Yao, Zhifeng [1 ,2 ]
Ge, Junbo [1 ,2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
ANGIOGRAPHIC PATTERNS; BARE-METAL; NEOATHEROSCLEROSIS; IMPLANTATION; INJURY; RISK;
D O I
10.1155/2017/8730271
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Late in-stent restenosis (ISR) has raised concerns regarding the long-term efficacy of drug-eluting stents (DES). The role of vascular endothelial growth factor (VEGF) in the pathological process of ISR is controversial. This retrospective study aimed to investigate the relationship between serum VEGF levels and late ISR in patients with DES implantation. A total of 158 patients who underwent angiography follow-up beyond 1 year after intervention were included. The study population was classified into ISR and non-ISR groups. The ISR group was further divided according to follow-up duration and Mehran classification. VEGF levels were significantly lower in the ISR group than in the non-ISR group [96.34 (48.18, 174.14) versus 179.14 (93.59, 307.74) pg/mL, P < 0.0001]. Multivariate regression revealed that VEGF level, procedure age, and low-density lipoprotein cholesterol were independent risk factors for late ISR formation. Subgroup analysis demonstrated that VEGF levels were even lower in the very late (>= 5 years) and diffuse ISR group (Mehran patterns II, III, and IV) than in the late ISR group (1-4 years) and the focal ISR group (Mehran pattern I), respectively. Furthermore, significant difference was found between diffuse and focal ISR groups. Serum VEGF levels were inversely associated with late ISR after DES implantation.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Findings Supporting Drug Resistance in the Treatment of In-Stent Restenosis Within Drug-Eluting Stents
    Byrne, Robert Albert
    Mehilli, Julinda
    Massberg, Steffen
    Laugwitz, Karl-Ludwig
    Pache, Juergen
    Schoemig, Albert
    Kastrati, Adnan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (20) : B4 - B4
  • [32] Differences in clinical presentation of in-stent restenosis between bare metal versus drug-eluting stents
    Villanueva Benito, I.
    Solla Ruiz, I.
    Paredes Galan, E.
    Bastos Fernandez, G.
    Gomez Blazquez, I.
    De Miguel, A.
    Jimenez Diaz, V.
    Ortiz Saez, A.
    Baz Alonso, J. A.
    Iniguez Romo, A.
    EUROPEAN HEART JOURNAL, 2011, 32 : 745 - 746
  • [33] Differences in clinical presentation of in-stent restenosis between bare metal versus drug-eluting stents
    Villanueva Benito, I.
    Solla Ruiz, I.
    Paredes Galan, E.
    Bastos Fernandez, G.
    Gomez Blazquez, I.
    De Miguel, A.
    Jimenez Diaz, V.
    Ortiz Saez, A.
    Baz Alonso, J. A.
    Iniguez Romo, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 : 745 - 746
  • [34] An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents
    Katsaros, Katharina M.
    Kastl, Stefan P.
    Krychtiuk, Konstantin A.
    Hutter, Randolph
    Zorn, Gerlinde
    Maurer, Gerald
    Huber, Kurt
    Wojta, Johann
    Christ, Guenter
    Speidl, Walter S.
    EUROINTERVENTION, 2014, 10 (02) : 224 - 230
  • [35] Use of drug-eluting stents for the treatment of in-stent restenosis in routine clinical practice
    Belardi, JA
    Cura, F
    Albertal, M
    Padilla, L
    Solioz, G
    Balino, PP
    Pascua, JA
    Fava, C
    Berrocal, D
    Mendiz, O
    Grinfeld, L
    CORONARY ARTERY DISEASE, 2005, 16 (05) : 327 - 330
  • [36] Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis
    Eisenberg, Mark J.
    Konnyu, Kristin J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (03): : 375 - 382
  • [37] In-Stent Restenosis After Femoropopliteal Interventions With Drug-Eluting Stents Same But Different?
    Sobieszczyk, Piotr
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (08) : 835 - 837
  • [38] Management of in-stent restenosis - Intracoronary brachytherapy vs drug-eluting stents.
    Sadiq, I
    Athar, H
    Ahmed, A
    Papaioannou, G
    Ashir, R
    Ameti, L
    Mennet, R
    Kiernan, F
    McKay, R
    Elkoustaf, R
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (6A): : 147E - 147E
  • [39] Drug-eluting stents: new presumed effects over in-stent restenosis prevention
    Macovei, Liviu
    Magopet, Robert
    Campo, Gianluca
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2021, 69 (02) : 141 - 143
  • [40] DRUG-ELUTING STENTS CONTAINING IBUPROFEN: A NOVEL STRATEGY TO REDUCE RESTENOSIS AND PREVENT LATE IN-STENT THROMBOSIS
    Giraldo, A.
    Dannoura, A.
    Pereira, I.
    Dash, P.
    Gibbins, J.
    Brooks, G.
    Bicknell, K.
    HEART, 2013, 99